非小细胞肺癌靶向治疗的研究进展(4)
[15] Ninomiya T，Takigawa N，Ichihara E，et al.Afatinibprolongs survival compared with gefitinib in an epidermal growth factor receptor-driven lung cancer model[J].Mol Cancer Ther，2013，12(5)：589-597.
[16] Katakami N，Atagi S，Goto K，et al.LUX-Lung 4：a phase Ⅱ trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib，gefitinib，or both[J].Journal of Clinical Oncology，2013，31(27)：3335-3341.
[17] Wang S，Song Y，Ya N F，et al.Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors[J].Front Med，2016，10(4)：1-6.
[18] Arcila M E，Oxnard G R，Nafa K，et al.Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid- based assay[J].Clin Cancer Res，2011，17(5)：1169-1180.
[19] Yu H，Arcila M E，Rekhtman N，et al.Analysis of tumor specimens at the time of acquired resistance to EGFR- TKI therapy in 155 patients with EGFR-mutant lung cancers[J].Clin Cancer Res，2013，19(8)：2240-2247.
[20]刘恕，李梦鹤，崔毅，等.第3代EGFR抑制剂Osimertinib Mesylate[J].藥学进展，2016，3(1)：74-80.
[21] Cross D A E，Ashton S E，Ghiorghiu S，et al.AZD9291，an irreversible EGFR TKI，overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer[J].Cancer discovery，2014，4(9)：1046-1061.
[22] J?nne P A，Yang J C H，Kim D W，et al.AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer[J].N Engl J Med，2015，363(18)：1689-1699.
[23]伍筱玫，丁选胜.用于非小细胞肺癌治疗的第三代EGFR-TKIs研究进展[J].药学进展，2016，3(11)：826-832.
[24]张卉，张树才.非小细胞肺癌EGFR基因靶向治疗研究进展[J].中国肺癌杂志，2017，20(1)：61-65.
[25] Wang S，Song Y，Liu D.EAI045：the fourth-generation EGFR inhibitor overcoming T790M and C797S resistance[J].Cancer Lette，2017(385)：51-54.
(收稿日期：2017-07-03), 百拇医药(孙佳颖 曲洪澜)
[16] Katakami N，Atagi S，Goto K，et al.LUX-Lung 4：a phase Ⅱ trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib，gefitinib，or both[J].Journal of Clinical Oncology，2013，31(27)：3335-3341.
[17] Wang S，Song Y，Ya N F，et al.Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors[J].Front Med，2016，10(4)：1-6.
[18] Arcila M E，Oxnard G R，Nafa K，et al.Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid- based assay[J].Clin Cancer Res，2011，17(5)：1169-1180.
[19] Yu H，Arcila M E，Rekhtman N，et al.Analysis of tumor specimens at the time of acquired resistance to EGFR- TKI therapy in 155 patients with EGFR-mutant lung cancers[J].Clin Cancer Res，2013，19(8)：2240-2247.
[20]刘恕，李梦鹤，崔毅，等.第3代EGFR抑制剂Osimertinib Mesylate[J].藥学进展，2016，3(1)：74-80.
[21] Cross D A E，Ashton S E，Ghiorghiu S，et al.AZD9291，an irreversible EGFR TKI，overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer[J].Cancer discovery，2014，4(9)：1046-1061.
[22] J?nne P A，Yang J C H，Kim D W，et al.AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer[J].N Engl J Med，2015，363(18)：1689-1699.
[23]伍筱玫，丁选胜.用于非小细胞肺癌治疗的第三代EGFR-TKIs研究进展[J].药学进展，2016，3(11)：826-832.
[24]张卉，张树才.非小细胞肺癌EGFR基因靶向治疗研究进展[J].中国肺癌杂志，2017，20(1)：61-65.
[25] Wang S，Song Y，Liu D.EAI045：the fourth-generation EGFR inhibitor overcoming T790M and C797S resistance[J].Cancer Lette，2017(385)：51-54.
(收稿日期：2017-07-03), 百拇医药(孙佳颖 曲洪澜)